Brief: OSE Immunotherapeutics Receives EUR 1.3 Mln Milestone Payment From Bpifrance
25/01/2021 06:35
Jan 25 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS RECEIVES €1.3 MILLION MILESTONE
PAYMENT
FROM BPIFRANCE FOR OSE-127/S95011
* MILESTONE AS PART OF COLLABORATIVE PROGRAM NAMED EFFIMAB
MARKS
CONTINUED CLINICAL PROGRESS
* INTERLEUKIN-7 RECEPTOR ANTAGONIST (IL-7R) OSE-127/S95011
IS
CURRENTLY IN A PHASE 2 CLINICAL TRIAL IN ULCERATIVE COLITIS,
SPONSORED BY OSE
Source text for Eikon: ID:nGNX2Nvk9R
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO